Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A74-A81 , June 2007

Molecular engineering of vein bypass grafts

  • Michael S. Conte, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Michael S. Conte, MD, Brigham and Women’s Hospital, Department of Vascular and Endovascular Surgery, 75 Francis St, Boston, MA 02115.

Received 29 January 2007 ,Accepted 11 February 2007.

References 

  1. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD, Donaldson MC. Impact of increasing comorbidity on infrainguinal reconstruction: a 20-year perspective. Ann Surg. 2001;233:445–452
  2. Conte MS. The ideal small arterial substitute: a search for the Holy Grail?. FASEB J. 1998;43–45
  3. Belkin M, Whittemore AD. Infrainguinal bypass. In:  Rutherford RB editors. Vascular surgery. 5th ed. Philadelphia: WB Saunders Co; 2000;p. 98–1018
  4. Schachner T, Laufer G, Bonatti J. In vivo (animal) models of vein graft disease. Eur J Cardiothorac Surg. 2006;30:451–463
  5. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 1991;34:45–68
  6. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg. 1995;9:7–18
  7. Conte MS, Mann MJ, Simosa HF, Rhynhart KK, Mulligan RC. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg. 2002;36:1040–1052
  8. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med. 2002;8:987–994
  9. Simosa HF, Wang G, Sui X, Peterson T, Narra V, Altieri DC, et al. Survivin expression is up-regulated in vascular injury and identifies a distinct cellular phenotype. J Vasc Surg. 2005;41:682–690
  10. Wang GJ, Sui XX, Simosa HF, Jain MK, Altieri DC, Conte MS. Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol. 2005;25:2081–2087
  11. Bafford R, Sui XX, Wang G, Conte M. Angiotensin II and tumor necrosis factor-alpha upregulate survivin and Kruppel-like factor 5 in smooth muscle cells: potential relevance to vein graft hyperplasia. Surgery. 2006;140:289–296
  12. Conte MS, Altieri DC. Survivin regulation of vascular injury. Trends Cardiovasc Med. 2006;16:114–117
  13. Friedmann T. Progress toward human gene therapy. Science. 1989;244:1275–1281
  14. Mulligan RC. The basic science of gene therapy. Science. 1993;260:926–932
  15. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995;270:404–410
  16. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33–40
  17. Wilson JM. Adenoviruses as gene delivery vehicles. N Engl J Med. 1996;334:1185–1187
  18. Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, et al. Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res. 1997;35:505–513
  19. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:2955–2965
  20. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated virus vectors for vascular gene delivery. Circ Res. 1997;80:497–505
  21. Eslami MH, Gangadharan SP, Sui X, Rhynhart KK, Snyder RO, Conte MS. Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors. J Vasc Surg. 2000;31:1149–1159
  22. Yang X, Atalar E, Li D, Serfaty JM, Wang D, Kumar A, et al. Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. Circulation. 2001;104:1588–1590
  23. Dishart KL, Denby L, George SJ, Nicklin SA, Yendluri S, Tuerk MJ, et al. Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. J Mol Cell Cardiol. 2003;35:739–748
  24. Colman A. Antisense strategies in cell and developmental biology. J Cell Sci. 1990;97:399–409
  25. Askari F, McDonnell W. Molecular medicine: antisense oligonucleotide therapy. N Engl J Med. 1996;334:316–318
  26. Zaug A, Been M, Cech T. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature. 1986;324:429–433
  27. Bielinska A, Schivdasani R, Zhang L. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science. 1990;250:997–1000
  28. Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;806–811
  29. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A. 1999;96:6411–6416
  30. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994;91:664–668
  31. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569–1572
  32. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444–10450
  33. Phelan A, Elliott G, O’Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol. 1998;16:440–443
  34. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2000;21:99–103
  35. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855–5859
  36. Mann MJ, Kernoff R, Dzau VJ. Vein graft gene therapy using E2F decoy oligonucleotides: target gene inhibition in human veins and long term resistance o atherosclerosis in rabbits. Surg Forum. 1997;48:242–244
  37. Ehsan A, Mann MJ, Dell’Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg. 2001;121:714–722
  38. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493–1498
  39. Grube E, Felderhoff T, Fitzgerald P, Terashima M, Gerckens U, Orav EJ, et al. PREVENT II: results of E2F decoy treatment of coronary vein bypass grafts (American Heart Association (Late Breaking Clinical Trials)). 2001;Anaheim, Calif
  40. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–751discussion 751
  41. Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovascular Surg. 2005;39:15–23
  42. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446–2454
  43. Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler Thromb Vasc Biol. 2004;24:470–476
  44. Owens CD, Wake N, Jacot JG, Gerhard-Herman M, Gaccione P, Belkin M, et al. Early biomechanical changes in lower extremity vein grafts--distinct temporal phases of remodeling and wall stiffness. J Vasc Surg. 2006;44:740–746
  45. Owens CD, Ridker PM, Belkin M, Hamdan AD, Pomposelli F, Logerfo F, et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007;45:2–9discussion 9
  46. Pierre-Paul D, Gahtan V, Conte M. Molecular biology and gene therapy in vascular disease. In:  Rutherford R editors. 6th ed. Vascular surgery. Vol 1:Philadelphia: Elsevier Saunders; 2005;p. 172–192

 This work has also been supported by funds from the Public Health Service (HL75771) and the Department of Surgery, Brigham and Women’s Hospital. The PREVENT trials were sponsored by Corgentech Inc (currently Anesiva, Inc, South San Francisco, Calif) and Bristol-Myers Squibb (Princeton, NJ).Competition of interest: Dr Conte has served as a paid consultant to Corgentech, Inc, and Bristol-Myers Squibb.

PII: S0741-5214(07)00317-5

doi: 10.1016/j.jvs.2007.02.031

Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A74-A81 , June 2007

Article Tools

* Image Usage & Resolution